Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Oct;130(11):1306-1316.
doi: 10.1111/1471-0528.17499. Epub 2023 Apr 19.

Progestogen maintenance therapy for prolongation of pregnancy after an episode of preterm labour: A systematic review and meta-analysis

Sofie H Breuking  1   2 , Annemijn A De Ruigh  1   2 , Frederik J R Hermans  1   2 , Ewoud Schuit  3   4 , C Andrew Combs  5 , Begoña Martinez de Tejada  6 , Martijn A Oudijk  2   7 , Ben W Mol  8 , Eva Pajkrt  1   2
Affiliations
Meta-Analysis

Progestogen maintenance therapy for prolongation of pregnancy after an episode of preterm labour: A systematic review and meta-analysis

Sofie H Breuking et al. BJOG. 2023 Oct.

Abstract

Background: Evidence for progestogen maintenance therapy after an episode of preterm labour (PTL) is contradictory.

Objectives: To assess effectiveness of progestogen maintenance therapy after an episode of PTL.

Search strategy: An electronic search in Central Cochrane, Ovid Embase, Ovid Medline and clinical trial databases was performed.

Selection criteria: Randomised controlled trials (RCT) investigating women between 16+0 and 37+0 weeks of gestation with an episode of PTL who were treated with progestogen maintenance therapy compared with a control group.

Data collection and analysis: Systematic review and meta-analysis were conducted. The primary outcome was latency time in days. Secondary neonatal and maternal outcomes are consistent with the core outcome set for preterm birth studies. Studies were extensively assessed for data trustworthiness (integrity) and risk of bias.

Main results: Thirteen RCT (1722 women) were included. Progestogen maintenance therapy demonstrated a longer latency time of 4.32 days compared with controls (mean difference [MD] 4.32, 95% CI 0.40-8.24) and neonates were born with a higher birthweight (MD 124.25 g, 95% CI 8.99-239.51). No differences were found for other perinatal outcomes. However, when analysing studies with low risk of bias only (five RCT, 591 women), a significantly longer latency time could not be shown (MD 2.44 days; 95% CI -4.55 to 9.42).

Conclusions: Progestogen maintenance therapy after PTL might have a modest effect on prolongation of latency time. When analysing low risk of bias studies only, this effect was not demonstrated. Validation through further research, preferably by an individual patient data meta-analysis is highly recommended.

Keywords: arrested preterm labour; meta-analysis; preterm birth; preterm labour; progesterone; progestogen; threatened preterm birth; threatened preterm labour; tocolysis.

PubMed Disclaimer

References

    1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162-72.
    1. Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Semin Perinatol. 2017;41(7):387-91.
    1. McPheeters ML, Miller WC, Hartmann KE, Savitz DA, Kaufman JS, Garrett JM, et al. The epidemiology of threatened preterm labor: a prospective cohort study. Am J Obstet Gynecol. 2005;192(4):1325-9; discussion 9-30.
    1. Hermans FJR, Bruijn MMC, Vis JY, Wilms FF, Oudijk MA, Porath MM, et al. Risk stratification with cervical length and fetal fibronectin in women with threatened preterm labor before 34 weeks and not delivering within 7 days. Acta Obstet Gynecol Scand. 2015;94(7):715-21.
    1. van Vliet EOG, Nijman TAJ, Schuit E, Heida KY, Opmeer BC, Kok M, et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016;387(10033):2117-24.

LinkOut - more resources